SOURCE: MMIT Analytics, as of 6/28/19
Tuesday, July 2, 2019
Sanofi and Regeneron's Dupixent last week scored an...
...FDA approval for a third
indication — the treatment of sinusitis with nasal polyps. The drug will be the
first biologic therapy to treat the condition. For the treatment of asthma,
Dupixent currently holds preferred status for just 1% of covered lives, growing
to 20% with prior authorization and/or step therapy. The therapy is not covered
for 13% of lives.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment